Korro Bio (NASDAQ:KRRO – Get Free Report) and Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.
Earnings & Valuation
This table compares Korro Bio and Cardio Diagnostics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Korro Bio | $6.39 million | 27.80 | -$117.26 million | ($10.00) | -1.21 |
| Cardio Diagnostics | $10,000.00 | 510.30 | -$6.50 million | ($2.92) | -0.59 |
Cardio Diagnostics has lower revenue, but higher earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings for Korro Bio and Cardio Diagnostics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Korro Bio | 1 | 2 | 6 | 3 | 2.92 |
| Cardio Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
Korro Bio currently has a consensus price target of $16.50, suggesting a potential upside of 36.79%. Given Korro Bio’s stronger consensus rating and higher possible upside, equities analysts clearly believe Korro Bio is more favorable than Cardio Diagnostics.
Volatility and Risk
Korro Bio has a beta of 3.13, meaning that its stock price is 213% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500.
Profitability
This table compares Korro Bio and Cardio Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Korro Bio | N/A | -114.26% | -68.57% |
| Cardio Diagnostics | -43,133.33% | -82.28% | -76.03% |
Insider and Institutional Ownership
13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 4.8% of Korro Bio shares are owned by company insiders. Comparatively, 9.0% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Korro Bio beats Cardio Diagnostics on 9 of the 15 factors compared between the two stocks.
About Korro Bio
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.
